Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial: Drug‐Coated Balloon for Coronary Indications: Too Little, Too Late

Editorial: Drug‐Coated Balloon for Coronary Indications: Too Little, Too Late Drug‐coated balloon (DCB) technology emerged over a decade ago as a remedy to restenosis. The technology developed after the introduction of drug‐eluting stents (DES) with the motivation to overcome the limitations and shortcomings of DES—primarily stent thrombosis, the need for prolonged dual antiplatelet therapy (DAPT), and difficulty to deliver the stents into small vessels or torturous vessels. Initially, DCBs were targeted for the treatment of bare metal stents (BMS). The DCB technology incorporated a paclitaxel drug with an antiproliferative mechanism loaded on an angioplasty balloon, using an excipient to enhance the solubility and the bioavailability of the paclitaxel and to improve the release of the drug into the vessel wall and to the adventitia. Unlike DES that elute the drug over several months, DCBs do not elute the drug. Rather, DCBs release the drug rapidly primarily during the inflation/deflation of the balloon, and therefore they should be named DCBs and not drug‐eluting balloons—as many authors wrongly call them, including Pastormerlo et al. who published an article on the technology in this issues of the journal. DCB technology developed simultaneously both for the coronary and for the peripheral indications. This editorial will be limited to the coronary indications. Early http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Editorial: Drug‐Coated Balloon for Coronary Indications: Too Little, Too Late

Journal of Interventional Cardiology , Volume 27 (6) – Dec 1, 2014

Loading next page...
 
/lp/wiley/editorial-drug-coated-balloon-for-coronary-indications-too-little-too-4wOMdiSIfM

References (5)

Publisher
Wiley
Copyright
"© 2014 Wiley Periodicals, Inc."
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/joic.12161
pmid
25421706
Publisher site
See Article on Publisher Site

Abstract

Drug‐coated balloon (DCB) technology emerged over a decade ago as a remedy to restenosis. The technology developed after the introduction of drug‐eluting stents (DES) with the motivation to overcome the limitations and shortcomings of DES—primarily stent thrombosis, the need for prolonged dual antiplatelet therapy (DAPT), and difficulty to deliver the stents into small vessels or torturous vessels. Initially, DCBs were targeted for the treatment of bare metal stents (BMS). The DCB technology incorporated a paclitaxel drug with an antiproliferative mechanism loaded on an angioplasty balloon, using an excipient to enhance the solubility and the bioavailability of the paclitaxel and to improve the release of the drug into the vessel wall and to the adventitia. Unlike DES that elute the drug over several months, DCBs do not elute the drug. Rather, DCBs release the drug rapidly primarily during the inflation/deflation of the balloon, and therefore they should be named DCBs and not drug‐eluting balloons—as many authors wrongly call them, including Pastormerlo et al. who published an article on the technology in this issues of the journal. DCB technology developed simultaneously both for the coronary and for the peripheral indications. This editorial will be limited to the coronary indications. Early

Journal

Journal of Interventional CardiologyWiley

Published: Dec 1, 2014

There are no references for this article.